Drug Interactions Dayvigo should not be taken with a strong or moderate CYP3A inducers as they could reduce its effectiveness. These include rifampin, carbamazepine, efavirenz, and etravirine. Special Considerations Special consideration should be given to patients with complex sleep behaviors such as sleep walking, patients with a compromised respiratory system, chronic depression, suicidal ideation, pregnancy, drug addiction and comorbid diagnosis Potential Side Effects/Toxicities Unusual drowsiness, generalized weakness and fatigue, sleep paralysis, somnambulism, allergic reactions, worsening depression or suicidal ideations. Dayvigo Nursing Indications he nurse should ensure that the patient is well educated on the drug use, especially the dosage and the potential side effects. The Nurse should also ensure patient safety by examining occupation,, sleep history and mental health of the patient fist. Patient Assessment The patient’s sleep disorder should be assessed as this drug can cause complex sleep disorders. The patient should also not be an operator of heavy machinery as the drug can cause drowsiness at work. The patient should not have a history of sleep paralysis of sleep walking as the drug can make them worse. Special considerations. Women who are pregnant should be given special consideration. The drug should not be prescribed to children. Drug addicts and people with liver impairment should be given special consideration too. Side Effect management The medication should be changed if serious side effects are experienced. Regular users should undergo regular liver function tests to determine if it is being affected. Patients who experience of exhibit signs of depression should cease using the drug. The dosage should be at the minimum affective level to avoid overdose toxicity. The medication should only be taken immediately before getting into bed. The dosage and schedule given by the doctor in the prescription should always be strictly followed. Patient Education Patient should not be an addict and should not take alcohol. Any episodes of sleep paralysis, muscle weakness or sleep activity should be reported promptly. The patient can experience daytime sleepiness when using the drug, so caution should be taken to avoid causing accidents Usage of he medication should be ceased immediately if once s the patient is pregnant. Drug Description Dayvigo is a lemborexant of the sedative-hypnotics class. It is an oral tablet whose dosage should not exceed 10mg It can be co-administered with a CYP3A inhibitor Dayvigo treats insomnia by blocking the binding sites of the wake promoting neuropeptides Orexin A and Orexin B, thereby suppressing wake drive causing drowsiness. 3 Pharmacology Brochure Discussion Elizabeh Jusu Chamberlin University College of Nursing Nursing Lisa South 9th December, 2021 Pharmacology Brochure Discussion This brochure introduces a recent medication that was approved by the FDA but has not been in ...

1. Drug Interactions
Dayvigo should not be taken with a strong or moderate CYP3A
inducers as they could reduce its effectiveness. These include
rifampin, carbamazepine, efavirenz, and etravirine.
Special Considerations
Special consideration should be given to patients with complex
sleep behaviors such as sleep walking, patients with a
compromised respiratory system, chronic depression, suicidal
ideation, pregnancy, drug addiction and comorbid diagnosis
Potential Side Effects/Toxicities
Unusual drowsiness, generalized weakness and fatigue, sleep
paralysis, somnambulism, allergic reactions, worsening
depression or suicidal ideations.
Dayvigo
Nursing Indications
he nurse should ensure that the patient is well educated on the
drug use, especially the dosage and the potential side effects.
The Nurse should also ensure patient safety by examining
occupation,, sleep history and mental health of the patient fist.
Patient Assessment
The patient’s sleep disorder should be assessed as this drug can
cause complex sleep disorders. The patient should also not be
an operator of heavy machinery as the drug can cause
drowsiness at work. The patient should not have a history of
sleep paralysis of sleep walking as the drug can make them
worse.
Special considerations.
Women who are pregnant should be given special consideration.
The drug should not be prescribed to children. Drug addicts and
people with liver impairment should be given special
consideration too.

2. Side Effect management
The medication should be changed if serious side effects are
experienced.
Regular users should undergo regular liver function tests to
determine if it is being affected.
Patients who experience of exhibit signs of depression should
cease using the drug.
The dosage should be at the minimum affective level to avoid
overdose toxicity.
The medication should only be taken immediately before getting
into bed.
The dosage and schedule given by the doctor in the prescription
should always be strictly followed.
Patient Education
Patient should not be an addict and should not take alcohol.
Any episodes of sleep paralysis, muscle weakness or sleep
activity should be reported promptly.
The patient can experience daytime sleepiness when using the
drug, so caution should be taken to avoid causing accidents
Usage of he medication should be ceased immediately if once s
the patient is pregnant.
Drug Description
Dayvigo is a lemborexant of the sedative-hypnotics class. It is
an oral tablet whose dosage should not exceed 10mg
It can be co-administered with a CYP3A inhibitor
Dayvigo treats insomnia by blocking the binding sites of the
wake promoting neuropeptides Orexin A and Orexin B, thereby
suppressing wake drive causing drowsiness.
3
Pharmacology Brochure Discussion

3. Elizabeh Jusu
Chamberlin University College of Nursing
Nursing
Lisa South
9th December, 2021
Pharmacology Brochure Discussion
This brochure introduces a recent medication that was approved
by the FDA but has not been in the market for long. It is a
source of quick information but covers most of the essential
areas of information that a nurse would need to have on their
fingertips concerning the drug. Dayvigo is a sleeping pill that
was approved in 2019, and whose effectiveness is quite high
(FDA 2020). The drug is a lemborexant of the sedative-
hypnotics class. It is an oral tablet whose dosage should not
exceed 10mg. When co-administered with a CYP3A inhibitor,
the dosage should be kept at only 5mg (Drugs.com, 2021). It is
an effective medication for treating insomnia but can have
serious side effects so it is essential for nurses to be well aware
of its use, contraindications, side effects and other potential
issues that could arise from its use.
The role of this brochure was to educate nurses on the existence
and use of Dayvigo, an insomnia treatment medication that was
recently introduced into the market. The brochure ought to offer
all the critical information that nurses and pharmacists need to
grasp promptly to effectively use the drug and achieve its full
potential as an anti-insomnia medication. It is designed to offer
detailed, verifiable and essential information on the drug to
nurses and other users quickly and efficiently. It is not meant to
be the definite primary education material on the drug, but a
quick source of refreshing information on the drug. The
brochure will be printed in an easily legible font and has a lot
of information on most of the topics which a nurse would
typically need to gather before issuing or when matching a
patient to a prescription.

4. References
Drugs.com. (2021). Lemborexant. Day ago. Full Drug
Information. https://www.drugs.com/mtm/lemborexant.html
Food and Drgug Administration (2020). Drug Approval
Package- Dayvigo.
https://www.google.com/search?q=DAyvigo+FDa&oq=DAyvigo
+FDa&aqs=chrome..69i57j35i39l2j0i512l4j69i60.3636j1j7&sou
rceid=chrome&ie=UTF-8
NR293 Pharmacology for Nursing Practice
Medication Teaching Plan Guidelines
NR293_RUA_Medication_Teaching_Plan_Guidelines_V3.docx
1
Purpose
The purpose of this assignment is for the student to synthesize
pharmacological knowledge (i.e., core drug
knowledge, core patient variables, and nursing implications) of
pharmacotherapeutic agents into a useful
teaching and learning tool for nurses and patients.
Course outcomes: This assignment enables the student to meet
the following course outcomes:
CO1 Apply the concepts of pharmacotherapeutics,
pharmacokinetics, pharmacodynamics, and pharmacogenomics
to
the use of specific medication classifications in specific health
conditions and in consideration of medication

5. side/adverse effects, nursing implications, and medication
teaching. (POs 1, 2, and 3)
CO2 Apply principles of health promotion, as well as illness
and injury prevention, to promote safety and effectiveness
of commonly used pharmacologic therapy across the lifespan,
taking into consideration sociocultural,
genetic/genomic, developmental, and gender implications. (POs
3 and 8)
CO3 Utilize the nursing process in understanding the effects of
drug therapy on health outcomes across the lifespan
within the framework of a diverse population of individuals,
families, and communities. (PO 4)
Due date: Your faculty member will inform you when this
assignment is due . The Late Assignment Policy applies
to this assignment.
Total points possible: 100 points
Preparing the assignment
Follow these guidelines when completing this assignment.
Speak with your faculty member if you have questions.
1. Choose a pharmacological agent that has been on the market
less than 5 years.
2. Research the literature and obtain two to three resources for
current, evidence-based information related to the
pharmacological agent.

6. 3. Develop a teaching brochure and one page paper following
these guidelines.
a. Brochure
• Key/Relevant Drug Information (30 points/30%)
o Drug Class
o Mechanism of Action
o Drug Administration and Dosage
o Drug Interactions
o Lab effects/interference
o Special Considerations
o Potential Side Effects/Adverse Effects/Toxicities
• Patient Education Considerations (35 points/35%)
o Nursing Management
o Patient Education Considerations
o Patient Assessment
o Side Effects/Adverse Effects/Toxicities
o Special considerations
• Visual Effects/Creativity (10 points/10%)
o Developed per the required standard
o Appropriate for the intended audience
o Flesch-Kincaid reading level seventh grade or lower
o Graphics enhance the purpose of the brochure
o Brochure is visually appealing
NR293 Pharmacology for Nursing Practice
Medication Teaching Plan Guidelines
NR293_RUA_Medication_Teaching_Plan_Guidelines_V3.docx
2

7. b. One Page Paper (15 points/15%)
• Describes intended brochure audience
• Describes intended use of brochure
• Includes
o Name
o Date
o Class
o Reference page
c. APA Format (5 points/5%)
• Includes no more than 3 unique errors with APA format
(current ed.)
• At least two (2) scholarly, primary sources from the last 5
years, excluding the textbook, are provided
d. Writing and Mechanics (5 points/5%)
• Clearly written
• Includes no more than three unique errors of grammar
• Includes no more than three unique errors in writing
mechanics
• Paper is one page, excluding references and title page
For writing assistance, visit the Writing Center.
Please note that your instructor may provide you with additional
assessments in any form to determine that you
fully understand the concepts learned in the review module.
https://library.chamberlain.edu/APA
NR293 Pharmacology for Nursing Practice
Medication Teaching Plan Guidelines

8. NR293_RUA_Medication_Teaching_Plan_Guidelines_V3.docx
3
Grading Rubric: Criteria are met when the student’s application
of knowledge demonstrates achievement of the outcomes for
this assignment.
Assignment Section and
Required Criteria
(Points possible/% of total points available)
Highest Level of
Performance
High Level of
Performance
Satisfactory Level
of Performance
Unsatisfactory
Level of
Performance
Section not
present in
paper
Brochure: Relevant Drug Information
(30 points/30%)
30 points 26 points 23 points 22 points 0 points
Required criteria

9. 1. Drug Class
2. Mechanism of Action
3. Drug Administration and Dosage
4. Drug Interactions
5. Lab effects/interference
6. Special Considerations
7. Potential Side Effects/Adverse Effects/Toxicities
Includes no fewer
than 7 requirements
for section.
Includes no fewer
than 6
requirements for
section.
Includes no fewer
than 5
requirements for
section.
Includes 1-4 criteria
for section.
No requirements
for this section
present
Brochure: Patient Education Considerations

10. (35 points/35%)
35 points 28 points 26 points 23 points 0 points
Required criteria
1. Nursing Management
2. Patient Education Considerations
3. Patient Assessment
4. Side Effects/Adverse Effects/Toxicities
5. Special Considerations
Includes no fewer
than 5 requirements
for section.
Includes no fewer
than 4
requirements for
section.
Includes no fewer
than 3 requirements
for section.
Includes 1-2
requirements for
section.
No requirements
for this section
present.

11. Brochure: Visual Effects/Creativity
(10 points/10%)
10 points 8 points 7 points 4 points 0 points
Required criteria
1. Developed per the required standard
2. Appropriate for the intended audience
3. Flesch-Kincaid reading level seventh grade or lower
4. Graphics enhance the purpose of the brochure
5. Brochure is visually appealing
Includes no fewer
than 5 requirements
for section.
Includes no fewer
than 4 requirements
for section.
Includes no fewer
than 3 requirements
for section.
Includes 1-2
requirements for
section.
No requirements
for this section
present.

12. One Page Paper
(15 points/15%)
15 points 12 points 11 points 8 points 0 points
Required criteria
1. Describes intended brochure audience
2. Describes intended use of brochure
3. Includes
Includes no fewer
than 6
requirements for
section.
Includes no fewer
than 5
requirements for
section.
Includes no fewer
than 4
requirements for
section.
Includes 1-3 criteria
for section.
No requirements
for this section
present.

13. NR293 Pharmacology for Nursing Practice
Medication Teaching Plan Guidelines
NR293_RUA_Medication_Teaching_Plan_Guidelines_V3.docx
4
Assignment Section and
Required Criteria
(Points possible/% of total points available)
Highest Level of
Performance
High Level of
Performance
Satisfactory Level
of Performance
Unsatisfactory
Level of
Performance
Section not
present in
paper
o Name
o Date
o Class

14. o Reference page
APA Format
(5 points/5%)
5 points 2 points 0 points
Required criteria
1. Includes no more than 3 unique errors with APA
format (current ed.)
2. At least two (2) scholarly, primary sources from the
last 5 years, excluding the textbook, are provided
Includes 2 requirements for section. Includes 1
requirement for
section.
No requirements
for this section
present.
Writing Mechanics
(5 points/5%)
5 points
4 points 2 points 0 points
Required criteria
1. Clearly written
2. Includes no more than three unique errors of
grammar

15. 3. Includes no more than three unique errors in
writing mechanics
4. Paper is 1 page, excluding title and reference pages
Includes no fewer than 4 requirements for
section.
Includes no fewer
than 3 requirements
for section.
Includes 1-2
requirements for
section.
No requirements
for this section
present.
Total Points Possible = 100 points